IBDEI051 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1674,1,4,0)
 ;;=4^H51.9
 ;;^UTILITY(U,$J,358.3,1674,2)
 ;;=^5006258
 ;;^UTILITY(U,$J,358.3,1675,0)
 ;;=H51.8^^16^166^2
 ;;^UTILITY(U,$J,358.3,1675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1675,1,3,0)
 ;;=3^Binocular Movement Disorders,Oth Spec
 ;;^UTILITY(U,$J,358.3,1675,1,4,0)
 ;;=4^H51.8
 ;;^UTILITY(U,$J,358.3,1675,2)
 ;;=^5006257
 ;;^UTILITY(U,$J,358.3,1676,0)
 ;;=H55.81^^16^166^30
 ;;^UTILITY(U,$J,358.3,1676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1676,1,3,0)
 ;;=3^Saccadic Eye Movements
 ;;^UTILITY(U,$J,358.3,1676,1,4,0)
 ;;=4^H55.81
 ;;^UTILITY(U,$J,358.3,1676,2)
 ;;=^5006373
 ;;^UTILITY(U,$J,358.3,1677,0)
 ;;=H55.89^^16^166^19
 ;;^UTILITY(U,$J,358.3,1677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1677,1,3,0)
 ;;=3^Irregular Eye Movements
 ;;^UTILITY(U,$J,358.3,1677,1,4,0)
 ;;=4^H55.89
 ;;^UTILITY(U,$J,358.3,1677,2)
 ;;=^5006374
 ;;^UTILITY(U,$J,358.3,1678,0)
 ;;=B39.9^^16^167^15
 ;;^UTILITY(U,$J,358.3,1678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1678,1,3,0)
 ;;=3^Histoplasmosis,Unspec
 ;;^UTILITY(U,$J,358.3,1678,1,4,0)
 ;;=4^B39.9
 ;;^UTILITY(U,$J,358.3,1678,2)
 ;;=^5000638
 ;;^UTILITY(U,$J,358.3,1679,0)
 ;;=E11.311^^16^167^9
 ;;^UTILITY(U,$J,358.3,1679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1679,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,1679,1,4,0)
 ;;=4^E11.311
 ;;^UTILITY(U,$J,358.3,1679,2)
 ;;=^5002632
 ;;^UTILITY(U,$J,358.3,1680,0)
 ;;=E11.319^^16^167^10
 ;;^UTILITY(U,$J,358.3,1680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1680,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,1680,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,1680,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,1681,0)
 ;;=E11.36^^16^167^7
 ;;^UTILITY(U,$J,358.3,1681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1681,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Cataract
 ;;^UTILITY(U,$J,358.3,1681,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,1681,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,1682,0)
 ;;=E11.39^^16^167^8
 ;;^UTILITY(U,$J,358.3,1682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1682,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Ophthalmic Complication
 ;;^UTILITY(U,$J,358.3,1682,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,1682,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,1683,0)
 ;;=E11.359^^16^167^11
 ;;^UTILITY(U,$J,358.3,1683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1683,1,3,0)
 ;;=3^Diabetes Type 2 w/ Prolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,1683,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,1683,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,1684,0)
 ;;=H35.30^^16^167^18
 ;;^UTILITY(U,$J,358.3,1684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1684,1,3,0)
 ;;=3^Macular Degeneration,Unspec
 ;;^UTILITY(U,$J,358.3,1684,1,4,0)
 ;;=4^H35.30
 ;;^UTILITY(U,$J,358.3,1684,2)
 ;;=^5005646
 ;;^UTILITY(U,$J,358.3,1685,0)
 ;;=H35.31^^16^167^17
 ;;^UTILITY(U,$J,358.3,1685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1685,1,3,0)
 ;;=3^Macular Degeneration,Nonexudative Age-Related
 ;;^UTILITY(U,$J,358.3,1685,1,4,0)
 ;;=4^H35.31
 ;;^UTILITY(U,$J,358.3,1685,2)
 ;;=^5005647
 ;;^UTILITY(U,$J,358.3,1686,0)
 ;;=H35.32^^16^167^16
 ;;^UTILITY(U,$J,358.3,1686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1686,1,3,0)
 ;;=3^Macular Degeneration,Exudative Age-Related
 ;;^UTILITY(U,$J,358.3,1686,1,4,0)
 ;;=4^H35.32
 ;;^UTILITY(U,$J,358.3,1686,2)
 ;;=^5005648
 ;;^UTILITY(U,$J,358.3,1687,0)
 ;;=H35.52^^16^167^29
 ;;^UTILITY(U,$J,358.3,1687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1687,1,3,0)
 ;;=3^Pigmentary Retinal Dystrophy
